Company intelligence / Profile preview

Hua Medicine

Shanghai, Shanghai, Chinahuamedicine.com ↗

Ownership: Private
Development stage: Commercial

Overview

HuaTangNing (dorzagliatin tablets, HMS5552) received approval from China's NMPA on September 30, 2022. Clinical trials demonstrated it can restore blood glucose homeostasis in T2D patients by repairing impaired glucokinase function. The SEED study showed potential for diabetes remission with 65.2% remission probability at week 52. The company recently completed its SENSITIZE study on the mechanism by which dorzagliatin improves β-cell glucose sensitivity.

Therapeutic areas: EndocrinologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

dorzagliatin

5 more assets in the full pipeline.

Beyond the preview

Go deeper on Hua Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hua Medicine.